Aravindan Vasudevan is the Co-founder and Chief Executive Officer of Actorius Innovations and Research Pvt. Ltd., a biotechnology and diagnostics company focused on advancing cancer detection and precision oncology technologies. With more than two decades of experience spanning pharmaceuticals, medical devices, and cancer diagnostics, he has played a pivotal role in translating complex scientific innovations into clinically relevant and commercially viable healthcare solutions.

At Actorius, Aravindan was part of the core team that developed OncoDiscover, a pioneering liquid biopsy technology and India’s first indigenously developed DCGI-approved in vitro diagnostic (IVD) platform for the detection and analysis of circulating tumor cells (CTCs). This technology represents a significant step forward in non-invasive cancer diagnostics, enabling clinicians to monitor disease progression and personalize treatment strategies through advanced blood-based testing.

Aravindan’s professional journey encompasses extensive experience in the pharmaceutical and medical device industries, including roles in manufacturing research and development, drug discovery, and technology commercialization. His expertise lies in building strategic pathways that enable the successful transition of scientific technologies from the research laboratory to real-world clinical and market applications. Over the years, he has contributed to the development of operational frameworks, regulatory strategies, and quality systems that support innovation-driven healthcare products.

In addition to his leadership role at Actorius, Aravindan is associated with multiple ventures and collaborative initiatives aimed at advancing technologies in cancer diagnostics, cancer genomics, and novel drug delivery systems. His work focuses on integrating research, regulatory compliance, and market readiness to accelerate the adoption of next-generation biomedical technologies.

Aravindan has significant experience navigating India’s regulatory landscape for medical devices. He has successfully developed and filed multiple regulatory dossiers under the Medical Device Rules, 2017 with the Central Drugs Standard Control Organization (CDSCO), Government of India, contributing to the regulatory approval and commercialization of innovative diagnostic technologies. He has also led the implementation of ISO 13485:2016 Quality Management Systems for medical device manufacturing, ensuring compliance with global quality standards.

Beyond regulatory and commercialization expertise, Aravindan is an IRCA Certified ISO 13485:2016 Lead Auditor from the British Standards Institute (BSI) and a Certified Medical Device Professional (CMDP). His professional training and certifications reflect a deep understanding of quality systems, regulatory frameworks, and global medical device standards.

Aravindan holds both his Bachelor of Science and Master of Science degrees in Chemistry from the University of Mumbai. He further expanded his business and strategic management capabilities through a Certificate in Business Studies (Marketing) from UCLA Extension. In recognition of his entrepreneurial potential and contributions to innovation, he was also selected to participate in the Cornell Maha 60 Accelerator Program, a long-term initiative by Cornell University in partnership with the Department of Industries, Government of Maharashtra, designed to support high-impact technology entrepreneurs.

With over 20 years of combined experience in pharmaceuticals and medical devices, Aravindan continues to drive innovation in oncology diagnostics, focusing on technologies that enable early detection, precision treatment decisions, and improved outcomes for cancer patients. Through his leadership at Actorius, he remains committed to advancing accessible, indigenous healthcare technologies that address critical challenges in cancer care.